ID: h-72c719461c
Hypothesis
C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD
Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function.
EvidencePending (0%)📖 8 cit🗣 2 debates✓ 8 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsufficiency vs. gain-of-function and whether TDP-43 inclusions represent a reversible state.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["C9orf72 Hexanucleotide<br/>G4C2 Repeat Expansion"]
B["Sense + Antisense<br/>RNA Foci Formation"]
C["DPR Proteins<br/>poly-GR / poly-PR"]
D["Nucleocytoplasmic<br/>Transport Impairment"]
E["Proteostasis<br/>Failure"]
F["Stress Granule<br/>Formation"]
G["Mitochondrial<br/>Dysfunction"]
H["Neurodegeneration<br/>ALS / FTD"]
A --> B
B --> C
B --> F
C --> D
D --> E
F --> E
E --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix8 supports2 contradicts
Supports
ALS-linked mutant TDP-43 in oligodendrocytes induces oligodendrocyte damage and exacerbates motor dysfunction in mice.
Supports
ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation.
Supports
TDP-43 toxic gain of function links ALS, FTD and Alzheimer's Disease through splicing dysregulation.
Supports
Sephin1 reduces TDP-43 cytoplasmic mislocalization and improves motor neuron survival in ALS models.
Contradicts
C9 haploinsufficiency vs. toxic gain-of-function contribution remains unresolved
Contradicts
TDP-43 pathology may represent a point-of-no-return beyond which nuclear TDP-43 localization is insufficient to restore splicing
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — C9ORF72
No curated PDB or AlphaFold mapping for C9ORF72 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for C9orf72 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for C9orf72.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
High
0.0610
Events (7d)
3
Price History
▼15.9%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C9orf72 ASO treatment reduces DPR levels in patient-derived iPSC motor neurons from C9-ALS/FTD subjects, THEN exon 32 splicing of UNC13A (a validated TDP-43 target) will normalize to levels compara | UNC13A exon 32 inclusion ratio ≥0.75 (normalized to control lines) and restoration of normal neurite length and survival to ≥80% of control values. | — no observation — | pending | 0.68 |
| IF C9orf72 ASOs (IONX-586 or equivalent) are administered to C9-BAC transgenic mice at 8 weeks of age (pre-symptomatic) for 12 weeks at 20 mg/kg via intracerebroventricular infusion, THEN CNS DPR prot | ≥50% reduction in cortical/spinal cord DPR aggregates and ≥30% restoration of nuclear TDP-43 immunoreactivity in motor neurons within 12 weeks of treatment onse | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF C9orf72 ASOs (IONX-586 or equivalent) are administered to C9-BAC transgenic mice at 8 weeks of age (pre-symptomatic) for 12 weeks at 20 mg/kg via intracerebroventricular infusion, THEN CNS DPR protein levels (poly-GA, poly-GR, poly-PR) will decrease by ≥50% (measured by ELISA) AND nuclear TDP-43
Predicted outcome: ≥50% reduction in cortical/spinal cord DPR aggregates and ≥30% restoration of nuclear TDP-43 immunoreactivity in motor neurons within 12 weeks of trea
Falsification: DPR protein levels unchanged or increased AND TDP-43 nuclear/cytoplasmic ratio shows no significant improvement (p>0.05) compared to vehicle, despite confirmed ASO uptake in CNS tissue.
pendingconf 68%
IF C9orf72 ASO treatment reduces DPR levels in patient-derived iPSC motor neurons from C9-ALS/FTD subjects, THEN exon 32 splicing of UNC13A (a validated TDP-43 target) will normalize to levels comparable to unaffected controls within 4 weeks of ASO exposure (10 μM, 14 days), with ≥40% restoration of
Predicted outcome: UNC13A exon 32 inclusion ratio ≥0.75 (normalized to control lines) and restoration of normal neurite length and survival to ≥80% of control values.
Falsification: UNC13A exon 32 splicing remains dysregulated (>20% deviation from disease baseline) AND neuronal survival shows no improvement despite confirmed DPR reduction (poly-GA ELISA) after ASO treatment.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.